Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPL | P05186 | 2/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 2/20 | 0.44 |
| ▸ | HTR2A | P28223 | 2/20 | 0.42 |
| ▸ | HTR2C | P28335 | 2/20 | 0.42 |
| ▸ | HTR2B | P41595 | 2/20 | 0.42 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.42 |
| ▸ | AR | P10275 | 1/20 | 0.38 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.38 |
| ▸ | TUBB | P07437 | 1/20 | 0.38 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.38 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.38 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.38 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.38 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.38 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.38 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.38 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.38 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.38 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4483125 | 0.90 | ALPL (0.47) | ALPLCYP19A1MAOBHTR2AHTR2C | |
| SCHEMBL4489426 | 0.90 | ALPL (0.47) | ALPLCYP19A1MAOBHTR2AHTR2C | |
| SCHEMBL4484219 | 0.84 | CYP19A1 (0.45) | ALPLCYP19A1HTR2AHTR2CGRIA1 | |
| SCHEMBL4495801 | 0.84 | CYP19A1 (0.45) | ALPLCYP19A1GRIA1AR | |
| SCHEMBL4485924 | 0.84 | CYP19A1 (0.45) | ALPLCYP19A1GRIA1AR | |
| SCHEMBL5986573 | 0.84 | CYP19A1 (0.45) | ALPLCYP19A1HTR2AHTR2CHTR2B | |
| SCHEMBL4492290 | 0.84 | CHRNB4 (0.42) | ALPLGRIA1AR | |
| SCHEMBL4489627 | 0.84 | CYP19A1 (0.45) | ALPLCYP19A1HTR2AHTR2CGRIA1 | |
| SCHEMBL4473337 | 0.82 | GRIA1 (0.39) | ALPLGRIA1AR | |
| SCHEMBL4489790 | 0.82 | GRIA1 (0.39) | ALPLGRIA1AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7504390-B2 | Benzoxazepine derivatives and their use as AMPA receptor stimulators | N.V. ORGANON (NL) | 2009-03-17 | — | — | US | disclosed |
| US-20080139529-A1 | BENZOXAPZEPINE DERIVATIVES AND THEIR USE AS AMPA RECEPTOR STIMULATORS | N.V. ORGANON (NL) | 2008-06-12 | — | — | US | disclosed |
| EP-1399450-B1 | BENZOXAZEPINE DERIVATIVES AND THEIR USE AS AMPA RECEPTOR STIMULATORS | ORGANON NV (NL) | 2008-03-19 | — | — | EP | disclosed |
| US-7307073-B2 | Benzoxazepines derivatives and their use as AMPA receptor stimulators | N.V. ORGANON (NL) | 2007-12-11 | — | — | US | disclosed |
| US-20040171605-A1 | Benzoxazepines derivatives and their use as ampa receptor stimulators | MERCK SHARP & DOHME B.V. (NL) | 2004-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171605-A1 | Benzoxazepines derivatives and their use as ampa receptor stimulators | CHRNA4, CHRNA10, CHRNA9 | ALPL 4303/4885CYP19A1 1855/4885MAOB 1149/4885 |
| US-20080139529-A1 | BENZOXAPZEPINE DERIVATIVES AND THEIR USE AS AMPA RECEPTOR STIMULATORS | GRIN1, GRIA4, CHRNA4 | ALPL 4457/4885CYP19A1 795/4885MAOB 923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.